These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 4015915)

  • 1. Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment.
    Timmis AD; Smyth P; Jewitt DE
    Br Heart J; 1985 Jul; 54(1):42-7. PubMed ID: 4015915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure.
    Maskin CS; Sinoway L; Chadwick B; Sonnenblick EH; Le Jemtel TH
    Circulation; 1983 May; 67(5):1065-70. PubMed ID: 6831672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Milrinone in heart failure. Acute effects on left ventricular systolic function and myocardial metabolism.
    Timmis AD; Smyth P; Monaghan M; Walker L; Daly K; McLeod AA; Jewitt DE
    Br Heart J; 1985 Jul; 54(1):36-41. PubMed ID: 4015914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.
    Baim DS; McDowell AV; Cherniles J; Monrad ES; Parker JA; Edelson J; Braunwald E; Grossman W
    N Engl J Med; 1983 Sep; 309(13):748-56. PubMed ID: 6888453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preload-dependent hemodynamic effects of milrinone in moderate heart failure.
    Remme WJ; van Hoogenhuyze DC; Kruijssen HA; Pieper PG; Bruggeling WA
    Cardiology; 1992; 80(2):132-42. PubMed ID: 1611632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure.
    Böhm M; Deutsch HJ; Hartmann D; Rosée KL; Stäblein A
    J Am Coll Cardiol; 1997 Oct; 30(4):992-6. PubMed ID: 9316529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic achievements of phosphodiesterase inhibitors and the future.
    Jewitt DE
    Eur Heart J; 1989 Aug; 10 Suppl C():53-9. PubMed ID: 2680498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Milrinone. A preliminary review of its pharmacological properties and therapeutic use.
    Young RA; Ward A
    Drugs; 1988 Aug; 36(2):158-92. PubMed ID: 3053125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.
    Monrad ES; McKay RG; Baim DS; Colucci WS; Fifer MA; Heller GV; Royal HD; Grossman W
    Circulation; 1984 Dec; 70(6):1030-7. PubMed ID: 6499142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.
    Monrad ES; Baim DS; Smith HS; Lanoue A; Brauwald E; Grossman W
    Circulation; 1985 May; 71(5):972-9. PubMed ID: 3986984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise responses before and after long-term treatment with oral milrinone in patients with severe heart failure.
    Ribeiro JP; White HD; Arnold JM; Hartley LH; Colucci WS
    Am J Med; 1986 Nov; 81(5):759-64. PubMed ID: 3535490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
    Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS
    J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good.
    Varriale P; Ramaprasad S
    Pharmacotherapy; 1997; 17(2):371-4. PubMed ID: 9085331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease.
    Sinoway LS; Maskin CS; Chadwick B; Forman R; Sonnenblick EH; Le Jemtel TH
    J Am Coll Cardiol; 1983 Aug; 2(2):327-31. PubMed ID: 6863765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study.
    Anderson JL; Baim DS; Fein SA; Goldstein RA; LeJemtel TH; Likoff MJ
    J Am Coll Cardiol; 1987 Apr; 9(4):711-22. PubMed ID: 3549837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of milrinone in patients with congestive heart failure--short- and long-term follow up studies.
    Nanimatsu H; Saikawa T; Maeda T; Fukuoka Y; Takaki R
    Jpn Circ J; 1993 Feb; 57(2):91-101. PubMed ID: 8450600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional blood flow and neurohormonal responses to milrinone in congestive heart failure.
    Cody RJ; Kubo SH; Covit AB; Müller FB; Rutman H; Leonard D; Laragh JH; Feldschuh J; Preibisz J
    Clin Pharmacol Ther; 1986 Feb; 39(2):128-35. PubMed ID: 3510799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure.
    Benotti JR; Lesko LJ; McCue JE; Alpert JS
    Am J Cardiol; 1985 Oct; 56(10):685-9. PubMed ID: 4050707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effects of intravenous milrinone in heart failure.
    Rettig GF; Schieffer HJ
    Eur Heart J; 1989 Aug; 10 Suppl C():39-43. PubMed ID: 2680496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a single oral dose of milrinone on left ventricular diastolic performance in the failing human heart.
    Piscione F; Jaski BE; Wenting GJ; Serruys PW
    J Am Coll Cardiol; 1987 Dec; 10(6):1294-302. PubMed ID: 3680800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.